Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and n-(6,7-difluoroquinolonyl)ampicillin

erlotinib hydrochloride has been researched along with n-(6,7-difluoroquinolonyl)ampicillin in 1 studies

Compound Research Comparison

Studies
(erlotinib hydrochloride)		Trials
(erlotinib hydrochloride)		Recent Studies (post-2010)
(erlotinib hydrochloride)		Studies
(n-(6,7-difluoroquinolonyl)ampicillin)		Trials
(n-(6,7-difluoroquinolonyl)ampicillin)		Recent Studies (post-2010) (n-(6,7-difluoroquinolonyl)ampicillin)
4,3537863,033604

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chen, M; Fan, Z; Feng, H; Hou, J; Li, F; Li, J; Li, YY; Liu, B; Pan, T; Sang, Q; Su, L; Wu, X; Yan, C; Yu, B; Yu, J; Yu, Y; Zang, M; Zhu, Z1

Other Studies

1 other study(ies) available for erlotinib hydrochloride and n-(6,7-difluoroquinolonyl)ampicillin

ArticleYear
BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C-MYC/PLCG1/Perk Axis.
    Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023, Volume: 10, Issue:34

    Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Phospholipase C gamma; Stomach Neoplasms

2023